Has Scott Herbert, MD received payments from drug or device companies?

Yes. Drug and device makers reported $268,161 in general payments to Scott Herbert, MD across 730 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Scott Herbert, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Scott Herbert, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Scott Herbert, MD

Hematology & Oncology · Albuquerque, NMNPI 1548340870

Payments from drug & device makers

$268,161in general payments, 2019–2025

Across 730 payments — averaging $367.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$136K
Merck$118K
Novartis$1K
AstraZeneca$1K
Gilead$960
E.r. Squibb & Sons, L.L.C.$846
plus $9K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	24	$136,242
Merck	31	$118,497
Novartis	76	$1,328
AstraZeneca(2 entities)	57	$1,138
Gilead(2 entities)	43	$960
E.r. Squibb & Sons, L.L.C.	53	$846
Johnson & Johnson	33	$835
Incyte Corporation	24	$713
Exelixis Inc.	20	$561
Bristol Myers Squibb	43	$511
Pfizer	36	$507
Seagen Inc.	29	$490
Genentech USA, Inc.	24	$446
Sanofi	11	$379
Takeda Pharmaceuticals U.S.A., Inc.	12	$376
Eisai Inc.	16	$325
AbbVie	11	$256
EMD Serono, Inc.	8	$255
Array Biopharma Inc	15	$209
Regeneron Healthcare Solutions, Inc.	7	$202
Blueprint Medicines Corporation	8	$201
Servier Pharmaceuticals LLC	9	$193
Beigene USA, Inc.	10	$192
Bayer	10	$192
Karyopharm Therapeutics Inc.	7	$145
Tersera Therapeutics LLC	6	$140
Lilly USA, LLC	8	$131
Zimmer Biomet	1	$111
Astellas Pharma US Inc	6	$104
GSK	6	$96
Amgen	5	$91
Sobi, Inc	4	$90
Stemline Therapeutics Inc.	4	$80
Pharmaessentia USA Corporation	5	$80
Puma Biotechnology, Inc.	4	$72
Springworks Therapeutics, Inc.	4	$71
Rigel Pharmaceuticals, Inc.	6	$69
Genmab U.S., Inc.	3	$68
Ipsen Biopharmaceuticals, Inc	3	$67
Boehringer Ingelheim	3	$65
Pharmacyclics LLC, An Abbvie Company	3	$61
Taiho Oncology, Inc.	4	$61
Jazz Pharmaceuticals Inc.	3	$55
Legend Biotech USA Inc.	3	$49
Deciphera Pharmaceuticals Inc.	2	$39
Mirati Therapeutics, Inc.	2	$36
Kyowa Kirin, Inc.	2	$33
Spectrum Pharmaceuticals Inc.	2	$32
US Oncology Corporate, Inc.	1	$32
Adaptive Biotechnologies Corporation	2	$31
Roche Diagnostics Corporation	2	$30
Geron Corporation	1	$29
Foundation Medicine, Inc.	1	$27
Menarini Silicon Biosystems, Inc.	1	$25
EUSA Pharma (US) LLC	2	$25
Acrotech Biopharma Inc.	1	$23
Agios Pharmaceuticals, Inc.	1	$22
Cycle Pharmaceuticals Inc	1	$22
Nuvation Bio Inc.	1	$21
Tempus AI, Inc	1	$21

How this compares

$268,161 in reported general payments places this provider in the 75th percentile of 54 hematology & oncology providers in New Mexico.

See all hematology & oncology providers in New Mexico →

Medicare billing

Part B allowed, 2024

$3,648,226

Medicare patients

469

Services billed

123,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Albuquerque

Ursa Brown GlabermanAlbuquerque$5M
Neda Hashemi SadraeiAlbuquerque$1.6M
Olivier RixeAlbuquerque$1.6M
Emrullah YilmazAlbuquerque$1.3M
Erika MaestasAlbuquerque$880K
Jose AvitiaAlbuquerque$553K
Jacklyn NemunaitisAlbuquerque$351K
Barbara McAnenyAlbuquerque$326K
Zoneddy DayaoAlbuquerque$319K
Yara AbdouAlbuquerque$294K

See the full list for New Mexico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →